STOCK TITAN

Anixa Biosciences Inc - ANIX STOCK NEWS

Welcome to our dedicated news page for Anixa Biosciences (Ticker: ANIX), a resource for investors and traders seeking the latest updates and insights on Anixa Biosciences.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Anixa Biosciences's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Anixa Biosciences's position in the market.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
Rhea-AI Summary
Anixa Biosciences announces the issuance of Canadian Patent 2,989,807, covering their novel CAR-T cancer treatment technology. The technology is being evaluated for the treatment of ovarian cancer in a Phase 1 clinical trial. The patent covers a nucleic acid that encodes a chimeric protein capable of binding to specific hormone receptors and activating T cells to treat certain types of cancer. The technology has potential applications beyond ovarian cancer and could be used to treat other solid tumors by exploiting an anti-angiogenesis mechanism of action.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.02%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.58%
Tags
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-24.46%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-24.46%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.19%
Tags
none
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.48%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.08%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.95%
Tags
none
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5%
Tags
management
Anixa Biosciences Inc

Nasdaq:ANIX

ANIX Rankings

ANIX Stock Data

101.12M
30.38M
4.9%
13.9%
1.81%
Computer Storage Device Manufacturing
Manufacturing
Link
US
San Jose

About ANIX

itus develops and acquires patented technologies for the purposes of patent monetization and patent assertion. the company currently has 8 patent portfolios in the areas of key based web conferencing encryption, encrypted cellular communications, nano field emission display (“nfed”), micro electro mechanical systems display (“mems”), j-channel window frame construction, vpn multicast communications, internet telephonic gateway, and enhanced auction technologies. itus’s management team has over 30 years of combined experience in patent monetization and patent assertion, and has generated in excess of $150 million patent licensing revenues